Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
6 hedge funds and large institutions have $130 invested in Titan Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
16% less capital invested
Capital invested by funds: $154 → $130 (-$24)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWL
Bogart Wealth LLC
Mclean,
Virginia
|
+$1 |
| 2 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$1 |
Top Sellers
TTNP Hedge Fund Activity: Q1 2026 in Review
6 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2026, worth a combined $130 — down 16% from $154 a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TTNP positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bogart Wealth LLC, opening a new position worth an estimated $1.
- 6 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2026, up from 4 in Q4 2025.
- Funds reported $130 of Titan Pharmaceuticals stock for Q1 2026, down 16% quarter-over-quarter.
- 2 funds opened new Titan Pharmaceuticals positions in Q1 2026 and 0 closed out, a net change of +2 holders.
- The largest Titan Pharmaceuticals buyer in Q1 2026 was Bogart Wealth LLC, an estimated $1 added.
Based on aggregated 13F filings for Q1 2026.